Protara Therapeutics, Inc. (TARA) Dividend History

Protara Therapeutics, Inc. (TARA) is a biotechnology company focused on developing innovative therapies for cancer and rare diseases. It is dedicated to advancing treatments through its pipeline of novel drug candidates, with an emphasis on targeted and personalized medicine approaches.

345 Park Avenue South, New York, NY, 10010
Phone: 646-844-0337
Website: http://www.protaratx.com

Dividend History

Protara Therapeutics, Inc. currently does not pay dividends

Company News

Protara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC

Protara Therapeutics announced positive interim results from its ongoing Phase 2 ADVANCED-2 trial of TARA-002, its investigational cell-based therapy, in patients with high-risk non-muscle invasive bladder cancer (NMIBC). The results showed high complete response rates and a favorable safety profile.

GlobeNewswire Inc.
Protara Highlights Recent Updates and Anticipated 2025 Milestones

Protara Therapeutics reported positive interim results from its ADVANCED-2 trial of TARA-002 in non-muscle invasive bladder cancer (NMIBC) patients. The company also expects to begin a pivotal trial for IV Choline Chloride and report data from its STARBORN-1 trial of TARA-002 in lymphatic malformations in 2025.

GlobeNewswire Inc.
Protara Announces Pricing of $100 Million Public Offering

Protara Therapeutics announced the pricing of a $100 million public offering, with plans to use the proceeds to fund the clinical development of TARA-002 and other programs.

GlobeNewswire Inc.
Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic Oncology

Protara Therapeutics announced that data from an interim analysis of the ongoing Phase 2 ADVANCED-2 trial of TARA-002 in patients with non-muscle invasive bladder cancer (NMIBC) will be presented at the upcoming Society of Urologic Oncology meeting. The trial is evaluating the safety and anti-tumor activity of TARA-002 in NMIBC patients.

GlobeNewswire Inc.
Protara Therapeutics Granted FDA Fast Track Designation for Intravenous Choline Chloride for Patients Receiving Parenteral Support

Protara Therapeutics has received FDA Fast Track designation for its investigational IV choline chloride therapy, which aims to address choline deficiency in patients dependent on parenteral support. The company plans to initiate a registrational trial in Q1 2025.

GlobeNewswire Inc.

Dividend data last updated 06/07/2025 11:39:51 UTC